GT BIOPHARMA, INC. Derivative, Gain (Loss) on Derivative, Net
GT BIOPHARMA, INC. (GTBP) reported Derivative, Gain (Loss) on Derivative, Net of $119.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2023-03-30
- GT BIOPHARMA, INC. derivative, gain (loss) on derivative, net for the quarter ending 2022-12-31 was $38.00K, a 77.38% decline year-over-year.
- GT BIOPHARMA, INC. derivative, gain (loss) on derivative, net for the quarter ending 2022-09-30 was $58.00K, a 88.45% decline year-over-year.
- GT BIOPHARMA, INC. derivative, gain (loss) on derivative, net for the quarter ending 2022-06-30 was $5.00K.
- GT BIOPHARMA, INC. derivative, gain (loss) on derivative, net for the quarter ending 2022-03-31 was $18.00K, a 14.29% decline year-over-year.
- GT BIOPHARMA, INC. derivative, gain (loss) on derivative, net for fiscal 2022 was $119.00K, a 43.60% decline from fiscal 2021.
- GT BIOPHARMA, INC. derivative, gain (loss) on derivative, net for fiscal 2021 was $211.00K.
- GT BIOPHARMA, INC. derivative, gain (loss) on derivative, net for fiscal 2020 was -$230.00K.
- GT BIOPHARMA, INC. derivative, gain (loss) on derivative, net for fiscal 2019 was $0.00.
| Period end | Derivative, Gain (Loss) on Derivative, Net 3 month | Derivative, Gain (Loss) on Derivative, Net 6 month | Derivative, Gain (Loss) on Derivative, Net 9 month | Derivative, Gain (Loss) on Derivative, Net 12 month | Derivative, Gain (Loss) on Derivative, Net 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $96.00K derived: sum of 2 quarters · filed 2023-03-30 | $101.00K derived: sum of 3 quarters · filed 2023-03-30 | $119.00K 10-K · filed 2023-03-30 | |
| 2022-09-30 | $58.00K 10-Q · filed 2022-10-31 | $63.00K derived: sum of 2 quarters · filed 2022-10-31 | $81.00K 10-Q · filed 2022-10-31 | $249.00K derived: sum of 4 quarters · filed 2023-03-30 | |
| 2022-06-30 | $5.00K 10-Q · filed 2022-08-15 | $23.00K 10-Q · filed 2022-08-15 | $191.00K derived: sum of 3 quarters · filed 2023-03-30 | $693.00K derived: sum of 4 quarters · filed 2023-03-30 | |
| 2022-03-31 | $18.00K 10-Q · filed 2022-05-16 | $186.00K derived: sum of 2 quarters · filed 2023-03-30 | $688.00K derived: sum of 3 quarters · filed 2023-03-30 | $208.00K derived: sum of 4 quarters · filed 2023-03-30 | |
| 2021-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $670.00K derived: sum of 2 quarters · filed 2023-03-30 | $190.00K derived: sum of 3 quarters · filed 2023-03-30 | $211.00K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $502.00K 10-Q · filed 2022-10-31 | $22.00K derived: sum of 2 quarters · filed 2022-10-31 | $43.00K 10-Q · filed 2022-10-31 | ||
| 2021-06-30 | -$480.00K 10-Q · filed 2022-08-15 | -$459.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $21.00K 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | -$230.00K 10-K · filed 2022-03-28 | $230.00K 10-K · filed 2021-04-16 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |